Investment Summary |
|
|---|---|
| Date | 2021-05-17 |
| Target | Hummingbird Bioscience |
| Sector | Life Science |
| Investor(s) | Polaris Partners |
| Deal Type | Venture |
SEARCH BY
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Polaris Partners is primarily a seed, first round, and early stage venture capital investor in information technology and life science businesses. However, Polaris also focuses on private equity investments in established companies. In this area, Polaris targets high growth middle market companies in industries including technology, healthcare, digital media, consumer products and services, and business services. The firm's investments include minority growth equity investments, recapitalizations with liquidity, and leveraged buyouts. Polaris Partners was formed in 1996 and has offices in Seattle, Washington and Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 70 of 87 |
| Sector: Life Science M&A | 25 of 39 |
| Type: Venture M&A Deals | 42 of 57 |
| Country: Singapore M&A | 1 of 3 |
| Year: 2021 M&A | 6 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-06 |
Dyno Therapeutics
Watertown, Massachusetts, United States Dyno Therapeutics is a biotechnology company applying artificial intelligence (AI) technology to discover novel AAV vectors with transformative properties, so that gene therapies can reach more patients and treat many more diseases. Dyno Therapeutics was founded in 2018 and is based in Watertown, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-26 |
Engine Biosciences
Singapore, Singapore Engine Biosciences is a drug discovery company using a proprietary AI and CRISPR-based platform to identify novel precision oncology targets. Engine Biosciences is based in Singapore. |
Buy | - |
